ReviewInvestigational new drugs2000
Proteasome inhibition: a new strategy in cancer treatment.
Review in Investigational new drugs, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 251 citations in OpenAlex.
- Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.Clinical lung cancer · 2011Trial
- Boron-containing anticancer agents: a target-centric review of structure-activity relationships and clinical pipeline.Archives of pharmacal research · 2025Review
- The Boron Advantage: The Evolution and Diversification of Boron's Applications in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.Medical oncology (Northwood, London, England) · 2021Article
- The Nrf2/PGC1Oxidative medicine and cellular longevity · 2020Article
- The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells.International journal of molecular sciences · 2019Article
- Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells.BMC cancer · 2019Article
- (Immuno)proteasomes as therapeutic target in acute leukemia.Cancer metastasis reviews · 2017Review
- Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Pathology and biology of radiation-induced cardiac disease.Journal of radiation research · 2016Review
- Nrf2 silencing to inhibit proteolytic defense induced by hyperthermia in HT22 cells.Redox biology · 2016Article
- Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.Neuro-oncology · 2016Article
- Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome.eLife · 2015Article
- The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma.Translational oncology · 2014Article
- Dynamics and evolution of β-catenin-dependent Wnt signaling revealed through massively parallel clonogenic screening.Integrative biology : quantitative biosciences from nano to macro · 2014Article
- Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).International journal of oncology · 2014Article
- Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.Journal of Cancer · 2014Article
- Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.Journal of neurosurgery · 2013Article
- A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.Leukemia research · 2013Article
- The unfolded protein response triggered by environmental factors.Seminars in immunopathology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitin proteasome pathway is a highly conserved intracellular pathway for the degradation of proteins. Many of the short-lived regulatory proteins which govern cell division, growth, activation, signaling and transcription are substrates that are temporally degraded by the proteasome. In recent years, new and selective inhibitors of the proteasome have been employed in cell culture systems to examine the anti-tumor potential of these agents. This review covers the chemistry of selected proteasome inhibitors, possible mechanisms of action in cell culture and the in vivo examination of proteasome inhibitors in murine and human xenograft tumor models in mice. One inhibitor, PS-341, has recently entered Phase I clinical trials in cancer patients with advanced disease to further test the potential of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.